Clinical trials: TCR-T Cells
TCR-T Cells, Refractory Solid Tumors
KSH01-TCRT Solid Tumors
1) Safety and efficacy of TCR-T cells in subjects with refractory/relapsed solid tumors. 2) The activation and proliferation of TCR-T cells in the subject, and the survival time.
- Conditions
- TCR-T Cells, Refractory Solid Tumors, Relapsed Solid Tumors
- Trial name
- KSH01-TCRT (NCT05539833)
- Testing
- KSH01 injection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- TCRx Therapeutics Co.Ltd
End Stage Renal Disease, Renal Transplant
Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection
Induction therapy with antibodies is administered during transplant surgery and for a short period of time following transplant surgery in an effort to render the immune system less able to mount an initial rejection response.
- Trial name
- NCT01154387
- Testing
- Anti-Thymocyte Globulin, TOL101, Steroids
- Where
- 12 sites in United States
- Volunteers
- 85 people
- Sponsor
- Tolera Therapeutics, Inc
Triple Negative Locally Advanced Non-resectable Breast Cancer, HR+, HER2-, Advanced Breast Cancer
A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors
This is a Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Combination with Sacituzumab…
- Trial name
- START-002 (NCT06827613)
- Testing
- STAR0602, Sacituzumab Govitecan (SG)
- Where
- 8 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Marengo Therapeutics, Inc.
Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer
EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma
MDG1015 is a third generation TCR-T therapy product targeting NY-ESO-1/LAGE-1a armored and enhanced by the PD1-41BB costimulatory switch protein (CSP).
- Conditions
- Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Soft Tissue Sarcoma (STS), Myxoid Liposarcoma
- Trial name
- EPITOME-1015-I (NCT06748872)
- Testing
- Lymphodepletion, TCR-T cells (MDG1015)
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Medigene AG
Sarcoma, Lung Cancers
An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors
This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.
- Conditions
- Sarcoma, Lung Cancers, Melanoma
- Trial name
- NCT06942143
- Testing
- Super1 TCR-T
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Guangzhou FineImmune Biotechnology Co., LTD.
Multiple Myeloma
Redirected Auto T Cells for Advanced Myeloma
The purpose of this study is to 1) evaluate the safety and tolerability of autologous genetically modified T cells transduced to express the high affinity NY-ESO-1c259 TCR in HLA-A2+ subjects and 2) measure the incidence of GVHD…
- Trial name
- NCT01352286
- Testing
- Autologous Genetically modified T cells
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Renal Clear Cell Carcinoma
Tissue Collection to ID TCRs From Renal Clear Cell Carcinoma Patients Responding to Immune Checkpoint Inhibitors
T Cell Receptor-engineered T-cell therapy (TCR T-cell therapy) offers a potentially transformative approach to treating cancer, but is currently limited by the lack of known targets (Maus and June, 2016; Ping et al., 2018).
- Trial name
- NCT04680416
- Where
- United States
- Sponsor
- TScan Therapeutics, Inc.
Ovarian Cancer
CT Antigen TCR-redirected T Cells for Ovarian Cancer.
This study, will take a subject's "T cells" and "teach" them to be able to recognize and attack the ovarian cancer cells. This is done by putting in a gene or genetic material that will change how a subject's T cells work and…
- Trial name
- NCT01567891
- Testing
- NYESO-1c259 T cells
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Adaptimmune
AML, MDS
A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA)
This is a multi-center, non-randomized, concurrent controlled, multi-arm, Phase 1 interventional, open-label, biologic assignment-based umbrella study evaluating the feasibility, safety and preliminary efficacy of an escalating…
- Trial name
- NCT05473910
- Testing
- SOC + TSC-101, Control, SOC + TSC-100
- Where
- 21 sites in United States
- Volunteers
- 310 people
- Sponsor
- TScan Therapeutics, Inc.
Advanced Solid Tumors
Treatment of Patients With Advanced Solid Tumors Using CRTKVA11-03 TCR-T Cell Injection
This is a single-center, open-label, single-arm, dose-escalation study aimed at evaluating the safety and preliminary efficacy of KRAS-specific autologous TCR-T cells in patients with advanced solid tumors harboring KRAS G12V…
- Trial name
- NCT07826585
- Testing
- CRTKVA11-03 TCR-T Cell Injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Corregene Biotechnology Co., Ltd
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Synovial Sarcoma
Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma
The purpose of this study is to evaluate the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide pre-treatment.
- Trial name
- NCT03250325
- Testing
- TBI-1301, Cyclophosphamide
- Where
- 5 sites in Japan
- Volunteers
- 8 people
- Sponsor
- Takara Bio Inc.
Synovial Sarcomas
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
The purpose of this study is to verify the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide/fludarabine pre-treatment.
- Trial name
- NCT07174427
- Testing
- TBI-1301, Cyclophosphamide, Fludarabine
- Where
- 3 sites in Japan
- Volunteers
- 5 people
- Sponsor
- Takara Bio Inc.
Uveal Melanoma
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
To evaluate the overall survival of HLA-A*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.
- Trial name
- NCT03070392
- Testing
- IMCgp100, Dacarbazine, Ipilimumab
- Where
- 57 sites in United States, Australia and 12 more
- Volunteers
- 378 people
- Sponsor
- Immunocore Ltd
Gynecologic Cancer, Colorectal Cancer
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors
- Conditions
- Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05194735
- Testing
- Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Alaunos Therapeutics
Hepatitis B, Chronic
Study of IMC-I109V in Non-cirrhotic HBeAg-negative Chronic HBV Infection
IMC-I109V is an immune-mobilizing monoclonal T cell receptor (TCR) against viruses (ImmTAV®), a new class of bispecific protein therapeutics designed for the treatment of chronic hepatitis B virus (HBV) infection (CHB).
- Trial name
- NCT05867056
- Testing
- IMC-I109V Single Ascending Dose, IMC-I109V Multiple Ascending Doses, HBV HCC Module MAD
- Where
- 15 sites in United States, Australia and 7 more
- Sponsor
- Immunocore Ltd
Cervical Cancer, Anal Cancer
CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers
A single center, open, single arm dose escalation phase I study to evaluate the safety, tolerability, and efficacy of CRTE7A2-01 TCR-T cell for HPV16 positive advanced cervical, anal, or head and neck cancers.
- Conditions
- Cervical Cancer, Anal Cancer, Head and Neck Cancers
- Trial name
- NCT05122221
- Testing
- Fludarabine + Cyclophosphamide, Interleukin-2, CRTE7A2-01 TCR-T Cell
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Corregene Biotechnology Co., Ltd
Acute Myeloid Leukemia
Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia
This study will be conducted to evaluate the safety, tolerability, cellular kinetics (CK), activity, and pharmacodynamics (PD) of NTLA-5001 in participants with Acute Myeloid Leukemia (AML).
- Trial name
- NCT05066165
- Testing
- Arm 1: NTLA-5001, Arm 2: NTLA-5001
- Where
- 10 sites in United States, United Kingdom
- Volunteers
- 6 people
- Sponsor
- Intellia Therapeutics
AML, ALL
A Long Term Follow-up Study of TScan TCR-T Products
The purpose of this Long-Term Follow-Up (LTFU) study is to monitor participants who have previously received TSC-100 or TSC-101 TCR-T therapies in the TSCAN-001 study.
- Conditions
- AML, ALL, MDS
- Trial name
- LTFU (NCT06976736)
- Testing
- Observational
- Where
- 2 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- TScan Therapeutics, Inc.
Esophagus Cancer, Hepatoma
Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies
This is a single arm, open-label, uni-center, phase I-II study to evaluate the safety and effectiveness of CAR-T/TCR-T cell immunotherapy in treating with different malignancies patients.
- Conditions
- Esophagus Cancer, Hepatoma, Glioma, Gastric Cancer
- Trial name
- NCT03941626
- Testing
- CAR-T/TCR-T cells immunotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shenzhen BinDeBio Ltd.